ANDA 62797, held by ACS Dobfar. Ampicillin Sodium.
As of Nov 21, 2026, ANDA 62797 (Ampicillin Sodium), held by ACS Dobfar, was first approved by FDA on Jul 12, 1993, with 5 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 12, 1993 | Original application | Approved | None posted |
| Ampicillin SodiumEQ 125MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| May 1, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Feb 15, 2018 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 15, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 15, 2018 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 25, 2004 | Supplement 1Labeling | Approved | None posted |
| Jul 12, 1993 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters